 |
|
Malignant Peripheral Nerve Sheath Tumors Associated With Neurofibromatosis Type 1
A Clinicopathologic and Molecular Study of 17 Patients
Karen Leroy, MD, PhD;
Valérie Dumas, MD;
Nadine Martin-Garcia, MSc;
Marie-Claude Falzone, MSc;
Marie-Catherine Voisin, MD;
Janine Wechsler, MD;
Jean Revuz, MD;
Alain Créange, MD;
Eric Levy, MD;
Laurent Lantieri, MD;
Jacques Zeller, MD;
Pierre Wolkenstein, MD, PhD
Arch Dermatol. 2001;137:908-913.
Objective To identify potential prognostic factors and criteria for early detection of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1 (NF1).
Design Retrospective study of malignant peripheral nerve sheath tumors in a cohort of 395 patients with NF1 followed up between October 1, 1988, and January 1, 1999; review of the clinical and histological characteristics of treatment and course; and analysis of p53 mutations and overexpression in tumors.
Setting Teaching hospital referral neurofibromatosis center for adults.
Patients Seventeen patients with NF1 (9 males and 8 females). Mean ± SD patient age at diagnosis was 32 ± 14 years.
Main Outcome Measures (1) Clinical symptoms, (2) comparison of p53 mutations and overexpression in benign vs malignant tumors; and (3) median survival.
Results Twelve patients had high-grade tumors. All tumors except 1 developed on preexisting nodular or plexiform neurofibromas. Pain and enlarging mass were the first and predominant signs. None of the benign tumors displayed significant p53 staining or p53 mutations. Six of 12 malignant tumors significantly overexpressed p53, and 4 of 6 harbored p53 missense mutations. Median survival was 18 months overall, 53 months in peripheral locations, and 21 months in axial locations.
Conclusions Malignant peripheral nerve sheath tumors are highly aggressive in NF1. They mostly arise from plexiform or nodular neurofibromas. Investigations and deep biopsy of painful and enlarging nodular or plexiform neurofibromas should be considered in patients with NF1. Late appearance of p53 mutations and overexpression precludes their use as predictive markers of malignant transformation.
From the Departments of Pathology (Drs Leroy, Voisin, and Wechsler and Mss Martin-Garcia and Falzone) and Dermatology (Drs Dumas, Revuz, Zeller, and Wolkenstein), Paris XII University, Henri-Mondor Hospital, Assistance Publique des Hôpitaux de Paris; and Réseau NF-Mondor (Drs Créange, Levy, and Lantieri), Créteil, France.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Relevance of Pathological Grades of Malignant Peripheral Nerve Sheath Tumor: A Multi-Institution TMTS Study of 56 Cases in Northern Japan
Okada et al.
Ann. Surg. Oncol. 2007;14:597-604.
ABSTRACT
| FULL TEXT
Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1
Levy et al.
Clin. Cancer Res. 2007;13:398-407.
ABSTRACT
| FULL TEXT
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity
Holtkamp et al.
Carcinogenesis 2006;27:664-671.
ABSTRACT
| FULL TEXT
Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature
Mensink et al.
J. Med. Genet. 2006;43:e08-e08.
ABSTRACT
| FULL TEXT
Neurofibromatosis 1-associated neuropathies: a reappraisal
Drouet et al.
Brain 2004;127:1993-2009.
ABSTRACT
| FULL TEXT
Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Identification of a Gene Expression Signature of Poor Prognosis
Levy et al.
Clin. Cancer Res. 2004;10:3763-3771.
ABSTRACT
| FULL TEXT
Review Article : Neurofibromas in Children With Neurofibromatosis 1
Rosser and Packer
J Child Neurol 2002;17:585-591.
ABSTRACT
Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients
Guillamo et al.
Brain 2002;126:152-160.
ABSTRACT
| FULL TEXT
|
